327 related articles for article (PubMed ID: 18242896)
1. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
[TBL] [Abstract][Full Text] [Related]
2. [The tissue distribution in mice and pharmacokinetics in rabbits of oridonin-solid lipid nanoparticles].
Zhang DR; Ren TC; Lou HX; Xing J
Yao Xue Xue Bao; 2005 Jun; 40(6):573-6. PubMed ID: 16144328
[TBL] [Abstract][Full Text] [Related]
3. In vivo studies on the oridonin-loaded nanostructured lipid carriers.
Zheng D; Dai W; Zhang D; Duan C; Jia L; Liu Y; Zhang Q
Drug Deliv; 2012 Aug; 19(6):286-91. PubMed ID: 22928767
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antitumor activity of oridonin nanosuspension.
Lou H; Zhang X; Gao L; Feng F; Wang J; Wei X; Yu Z; Zhang D; Zhang Q
Int J Pharm; 2009 Sep; 379(1):181-6. PubMed ID: 19563872
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of riccardin D nanosuspensions with different particle size.
Liu G; Zhang D; Jiao Y; Guo H; Zheng D; Jia L; Duan C; Liu Y; Tian X; Shen J; Li C; Zhang Q; Lou H
Colloids Surf B Biointerfaces; 2013 Feb; 102():620-6. PubMed ID: 23107940
[TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin.
Zhang P; Liu Y; Feng N; Xu J
Int J Pharm; 2008 May; 355(1-2):269-76. PubMed ID: 18242895
[TBL] [Abstract][Full Text] [Related]
7. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
Zhang X; Zhang T; Lan Y; Wu B; Shi Z
AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement.
Gao L; Zhang D; Chen M; Zheng T; Wang S
Drug Dev Ind Pharm; 2007 Dec; 33(12):1332-9. PubMed ID: 18097807
[TBL] [Abstract][Full Text] [Related]
9. An HPLC method for determination of oridonin in rabbits using isopsoralen as an internal standard and its application to pharmacokinetic studies for oridonin-loaded nanoparticles.
Mei Y; Xu J; Zhao J; Feng N; Liu Y; Wei L
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jun; 869(1-2):138-41. PubMed ID: 18514594
[TBL] [Abstract][Full Text] [Related]
10. Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery.
Liu Y; Zhang D; Duan C; Jia L; Xie P; Zheng D; Wang F; Liu G; Hao L; Zhang X; Zhang Q
J Microencapsul; 2012; 29(2):194-203. PubMed ID: 22172025
[TBL] [Abstract][Full Text] [Related]
11. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM
Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity.
Wang L; Liu Z; Liu D; Liu C; Juan Z; Zhang N
Int J Pharm; 2011 Jul; 413(1-2):194-201. PubMed ID: 21540085
[TBL] [Abstract][Full Text] [Related]
13. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development.
Sigfridsson K; Lundqvist AJ; Strimfors M
Drug Dev Ind Pharm; 2009 Dec; 35(12):1479-86. PubMed ID: 19929207
[TBL] [Abstract][Full Text] [Related]
14. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin.
Zheng D; Duan C; Zhang D; Jia L; Liu G; Liu Y; Wang F; Li C; Guo H; Zhang Q
Int J Pharm; 2012 Oct; 436(1-2):379-86. PubMed ID: 22732673
[TBL] [Abstract][Full Text] [Related]
15. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
Lai F; Sinico C; Ennas G; Marongiu F; Marongiu G; Fadda AM
Int J Pharm; 2009 May; 373(1-2):124-32. PubMed ID: 19429297
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma.
Xu W; Sun J; Zhang TT; Ma B; Cui SM; Chen DW; He ZG
Acta Pharmacol Sin; 2006 Dec; 27(12):1642-6. PubMed ID: 17112421
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery.
Wang Y; Zhang D; Liu Z; Liu G; Duan C; Jia L; Feng F; Zhang X; Shi Y; Zhang Q
Nanotechnology; 2010 Apr; 21(15):155104. PubMed ID: 20332565
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions.
Verma S; Gokhale R; Burgess DJ
Int J Pharm; 2009 Oct; 380(1-2):216-22. PubMed ID: 19596059
[TBL] [Abstract][Full Text] [Related]
19. Effects of oridonin nanosuspension on cell proliferation and apoptosis of human prostatic carcinoma PC-3 cell line.
Zhang Z; Zhang X; Xue W; Yangyang Y; Xu D; Zhao Y; Lou H
Int J Nanomedicine; 2010 Oct; 5():735-42. PubMed ID: 21042419
[TBL] [Abstract][Full Text] [Related]
20. The effect of stealth liposomes on pharmacokinetics, tissue distribution and anti-tumor activity of oridonin.
Wang C; Wei Y; Yu L; Zhang L
PDA J Pharm Sci Technol; 2009; 63(5):409-16. PubMed ID: 20158047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
